We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
-2.03%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$1.01B
AUM Growth
-$490M
Cap. Flow
-$415M
Cap. Flow %
-40.98%
Top 10 Hldgs %
28.64%
Holding
97
New
5
Increased
11
Reduced
69
Closed
8

Top Buys

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$18M
2
BNTX icon
BioNTech
BNTX
+$14.3M
3
ALGN icon
Align Technology
ALGN
+$7.3M
4
GDRX icon
GoodRx Holdings
GDRX
+$5.39M
5
CYTK icon
Cytokinetics
CYTK
+$5.15M

Top Sells

Rank Stock Value
1
UNH icon
UnitedHealth
UNH
+$29.9M
2
PFE icon
Pfizer
PFE
+$24.8M
3
JNJ icon
Johnson & Johnson
JNJ
+$23.8M
4
ELV icon
Elevance Health
ELV
+$23.7M
5
MCK icon
McKesson
MCK
+$22.3M

Sector Composition

Rank Sector Weight
1 Healthcare 98.1%
2 Industrials 1.09%
3 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LLY icon
1
Eli Lilly
LLY
$1.02T
$35.4M 3.49%
123,500
-46,500
-27% -$12M
HZNP
2
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$35.3M 3.49%
335,837
-89,163
-21% -$8.69M
ABBV icon
3
AbbVie
ABBV
$443B
$31.6M 3.12%
195,000
-140,000
-42% -$20.3M
UNH icon
4
UnitedHealth
UNH
$376B
$29.6M 2.92%
58,000
-62,000
-52% -$29.9M
MCK icon
5
McKesson
MCK
$100B
$29.1M 2.87%
95,000
-82,000
-46% -$22.3M
JAZZ icon
6
Jazz Pharmaceuticals
JAZZ
$15.9B
$28.3M 2.79%
181,976
-108,024
-37% -$15.7M
PFE icon
7
Pfizer
PFE
$143B
$27.1M 2.67%
522,500
-477,500
-48% -$24.8M
CI icon
8
Cigna
CI
$73.7B
$26.8M 2.65%
112,000
-28,000
-20% -$6.56M
CVS icon
9
CVS Health
CVS
$133B
$23.8M 2.35%
235,000
-175,000
-43% -$18.4M
VRTX icon
10
Vertex Pharmaceuticals
VRTX
$121B
$23.4M 2.3%
89,500
-75,500
-46% -$17.9M
ELV icon
11
Elevance Health
ELV
$81.5B
$22.7M 2.24%
46,199
-51,801
-53% -$23.7M
BSX icon
12
Boston Scientific
BSX
$69.5B
$22.6M 2.23%
510,000
-400,000
-44% -$17.3M
ABMD
13
DELISTED
Abiomed Inc
ABMD
$22.5M 2.22%
68,000
+16,000
+31% +$4.93M
ALNY icon
14
Alnylam Pharmaceuticals
ALNY
$27.5B
$21.2M 2.09%
130,000
-45,000
-26% -$6.86M
JNJ icon
15
Johnson & Johnson
JNJ
$618B
$20M 1.98%
113,000
-140,000
-55% -$23.8M
REGN icon
16
Regeneron Pharmaceuticals
REGN
$78.5B
$19.9M 1.96%
+28,500
New +$18M
COO icon
17
Cooper Companies
COO
$14.1B
$19.2M 1.9%
184,000
-33,040
-15% -$3.33M
APLS
18
DELISTED
Apellis Pharmaceuticals
APLS
$19.2M 1.89%
377,000
-53,000
-12% -$2.34M
MRK icon
19
Merck
MRK
$322B
$18.5M 1.82%
225,000
-75,000
-25% -$5.91M
MDT icon
20
Medtronic
MDT
$109B
$17.8M 1.75%
160,000
-136,000
-46% -$14.4M
THC icon
21
Tenet Healthcare
THC
$20.5B
$17.4M 1.72%
203,000
-7,000
-3% -$575K
ITCI
22
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$17.1M 1.69%
280,000
-110,000
-28% -$5.71M
BMRN icon
23
BioMarin Pharmaceuticals
BMRN
$11.6B
$17M 1.67%
220,000
-45,000
-17% -$3.77M
COR icon
24
Cencora
COR
$60.6B
$16.7M 1.65%
108,000
-110,000
-50% -$15.6M
BHVN
25
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$16.1M 1.59%
136,000
-14,000
-9% -$1.75M
1
2 3 4

Similar funds

BBI
Baxter Bros Inc Riverside, Connecticut $810M AUM 16.24% 1-Year Est. Return
SSG
Summit Securities Group New York $810M AUM 27.35% 1-Year Est. Return
PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
DWA
Dorsey Wright & Associates Pasadena, California $807M AUM 65.46% 1-Year Est. Return
SLG
Stanley-Laman Group Berwyn, Pennsylvania $814M AUM 40.24% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return

Rhenman & Partners Asset Management's Q1 2022 Portfolio in Review

As of Q1 2022, Rhenman & Partners Asset Management held 97 positions worth $1.01B, down 33% from $1.5B the previous quarter. Its ten largest holdings account for 29% of the portfolio.

Rhenman & Partners Asset Management withdrew a net $415M in Q1 2022, closing 8 positions and reducing 69 holdings. Its most notable exit was HCA Healthcare, an estimated $15.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 98% a quarter earlier, followed by Industrials and Technology.

Against the trend, Rhenman & Partners Asset Management opened a new position in Regeneron Pharmaceuticals worth $19.9M.

  • Rhenman & Partners Asset Management's largest Q1 2022 buy was Regeneron Pharmaceuticals: 28,500 shares worth $19.9M.
  • Rhenman & Partners Asset Management added most to Align Technology in Q1 2022, an estimated $7.3M increase.
  • Rhenman & Partners Asset Management's biggest Q1 2022 reduction was UnitedHealth, cutting an estimated $29.9M.
  • Rhenman & Partners Asset Management fully exited HCA Healthcare in Q1 2022, selling an estimated $15.2M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 29% of its $1.01B portfolio in Q1 2022.
  • Rhenman & Partners Asset Management opened 5 new positions and closed 8 in Q1 2022.
  • Rhenman & Partners Asset Management's portfolio value fell 33% quarter-over-quarter to $1.01B.

Based on Rhenman & Partners Asset Management's 13F filing for Q1 2022, filed 13 May 2022.